ReviewWorld journal of clinical cases2022
Role of visfatin in obesity-induced insulin resistance.
Review in World journal of clinical cases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 73 citations in OpenAlex.
- Comparative Effects ofNutrients · 2024Trial
- Incretin-based therapies and PPARγ agonists as regulators of adipokines-Nrf2 axis in diabetic cardiovascular disease.Global cardiology science & practice · 2026Review
- Adipose-Derived Proinflammatory Visfatin Promotes Vascular Calcification via TLR4 and is Suppressed by Empagliflozin.Inflammation · 2026Article
- Clustering adipokines, metabolic, oxidative stress, and inflammatory markers associated with cardiovascular disease risk in patients with metabolic syndrome.Diabetology & metabolic syndrome · 2026Article
- Insulin Resistance and Inflammation.International journal of molecular sciences · 2026Review
- Obesity and Its Clinical Implications in End-Stage Kidney Disease.Medicina (Kaunas, Lithuania) · 2026Review
- Adipokine patterns in type 1 and type 2 diabetes mellitus: comparative analysis of adiponectin-leptin ratio, visfatin, and TNF-α.Frontiers in endocrinology · 2026Article
- Citrus Essential Oil Nanoemulsions Mitigate Cardiac, Hepatic, and Pancreatic Injury in High-Fat Obese Rats via Adiponectin/SIRT1/Nrf2 Signaling Pathways.Journal of nutrition and metabolism · 2026Article
- Aging epicardial adipose tissue: a metabolic-endocrine network driving vascular calcification.Frontiers in endocrinology · 2026Review
- Perithyroidal Adipose Tissue Drives Thyroid Tumorigenesis through Adipokine Signaling and Immune Suppression.Research (Washington, D.C.) · 2026Article
- Integrated multi-omics and single-cell transcriptomic analysis reveals shared molecular mechanisms and cell-cell communication signatures in gout and metabolic syndrome.Frontiers in medicine · 2026Article
- Surgical removal of visceral adipose tissue has therapeutic benefit in male APPFrontiers in endocrinology · 2026Article
- Diosgenin in polyendocrine metabolic ovarian syndrome: modulation of insulin resistance, inflammation, steroidogenesis, and metabolic dysfunction.Frontiers in endocrinology · 2026Review
- Parallel Pathways, Divergent Outcomes: Adipose Tissue-Neural Crosstalk in Depression and Obesity.Journal of clinical medicine · 2025Review
- Investigation of Serum Visfatin and Chemerin Levels in Type 2 Diabetes and Obesity Patients: Their Potential Role as Clinical and Biomarkers.Biomedicines · 2025Article
- Role of Adipokines Chemerin, Visfatin, and Omentin in Obesity and Their Inflammatory and Metabolic Implications.Biomedicines · 2025Review
- Interplay of obesity and parasitic infection: current evidence of immunogenesis, tumorigenesis and leptin receptor involvement.Nutrition & metabolism · 2025Review
- Weight of time: exploring the link between obesity and aging.Aging clinical and experimental research · 2025Review
- Effects of peptides derived from active sites of visfatin on wound healing.Scientific reports · 2025Article
- Effect of adipokines on bone marrow mesenchymal stem cell function.World journal of stem cells · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The growing worldwide burden of insulin resistance (IR) emphasizes the importance of early identification for improved management. Obesity, particularly visceral obesity, has been a key contributing factor in the development of IR. The obesity-associated chronic inflammatory state contributes to the development of obesity-related comorbidities, including IR. Adipocytokines, which are released by adipose tissue, have been investigated as possible indicators of IR. Visfatin was one of the adipocytokines that attracted attention due to its insulin-mimetic activity. It is released from a variety of sources, including visceral fat and macrophages, and it influences glucose metabolism and increases inflammation. The relationship between visfatin and IR in obesity is debatable. As a result, the purpose of this review was to better understand the role of visfatin in glucose homeostasis and to review the literature on the association between visfatin levels and IR, cardiovascular diseases, and renal diseases in obesity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.